Form 4: AngioDynamics Executive Receives Stock and Options Grant

Lawrence T. Weiss, SVP and Chief Legal Officer at AngioDynamics, received a grant of restricted stock units and stock options.

Summary

• Lawrence T. Weiss, the SVP and Chief Legal Officer of AngioDynamics, received 52,697 restricted stock units, each representing a contingent right to receive one share of common stock.
• These restricted stock units will vest in four equal annual installments starting on December 2, 2025.
• Mr. Weiss also received 103,650 non-qualified stock options with an exercise price of $7.14.
• These stock options also vest in four equal annual installments beginning on December 2, 2025.
• Both the restricted stock units and stock options vest 25% each year on December 2nd, from 2025 to 2028.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to slightly positive as it aligns management with shareholders.

Positives

• The grant of restricted stock units and stock options aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock and option grants are a common form of executive compensation in publicly traded companies, designed to incentivize performance and align management's interests with shareholders.

Comparison to Industry Standards

• The vesting schedule of four equal annual installments is a standard practice for equity grants.
• The use of both restricted stock units and stock options is a common approach to executive compensation.
• The specific values of the grants would need to be compared to similar companies to determine if they are in line with industry standards.

Stakeholder Impact

• The stock and option grants may have a minor dilutive effect on existing shareholders.
• The grants are intended to motivate the executive to improve company performance, which would benefit all stakeholders.

Key Dates

Keywords

stock options, restricted stock units, executive compensation, insider trading, AngioDynamics, equity grant, vesting